Table 3 Antiseizure medications, immunotherapy and outcome of the studied patients
From: Neuronal autoantibodies in a sample of Egyptian patients with drug-resistant epilepsy
| Â | N | % |
|---|---|---|
Antiseizure medications (ASMs) | Â | Â |
 Carbamazepine | 16 | 64.00 |
 Phenytoin | 14 | 56.00 |
 Valproate | 12 | 48.00 |
 Levetiracetam | 8 | 32.00 |
 Lacosamide | 7 | 28.00 |
 Oxcarbazepine | 6 | 24.00 |
 Zonisamide | 5 | 20.00 |
 Eslicarbazepine | 4 | 16.00 |
 Topiramate | 4 | 16.00 |
 Clonazepam | 4 | 16.00 |
 Lamotrigine | 3 | 12.00 |
Immunomodulatory treatment | ||
 (Intravenous methylprednisolone) IVMP | 20 | 80.00 |
 (Intravenous immunoglobulin g) IVIg | 5 | 20.00 |
 Plasma exchange (PLEX) | 6 | 24.00 |
 Oral prednisolone | 2 | 8.00 |
 None | 3 | 12.00 |
Seizure outcome | ||
 Seizure freedom | 14 | 56.00 |
 50% reduction in seizure frequency | 9 | 36.00 |
 No improvement | 2 | 8.00 |
Seizure-associations outcome | ||
 None | 21 | 84.00 |
 Residual cognitive affection | 3 | 12.00 |
 Residual personality changes | 1 | 4.00 |